[43] Additionally, decreased BLVRA levels impaired oxidative stress and neuroprotection, resulting in increased tau phosphorylation in early-stage AD, suggesting that it is a promising therapeutic target for AD [44]. This evidence concerns the gene MAPT and Alzheimer disease.